Legend Biotech Reports Second Quarter 2025 Results and Recent Highlights — Neutral
LEGN GlobeNewsWire — August 11, 2025SOMERSET, N.J., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today reported its second quarter 2025 unaudited financial results and key corporate highlights.
Compass Therapeutics Reports 2025 Second Quarter Financial Results and Provides Corporate Update — Neutral
CMPX GlobeNewsWire — August 11, 2025BOSTON, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics, today reported second quarter 2025 financial results and provided a business update on its clinical and pre-clinical programs.
GT Biopharma Advances into Cohort 3 of GTB-3650 Phase 1 Trial Following Safety Review of Cohort 2 — Neutral
GTBP GlobeNewsWire — August 11, 2025The first patient in Cohort 3, the fifth patient in the trial, has completed the first week of cycle 1 following the successful safety review of Cohort 2 with no safety or tolerability issues observed The company plans on releasing initial Phase 1 results later in 2025 following completion of additional dose cohorts
Interpublic Partners with Aaru to Leverage AI-Powered Predictive Simulations to Accelerate, Scale and Optimize Marketing — Neutral
IPG GlobeNewsWire — August 11, 2025New York, NY, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Interpublic Group (NYSE: IPG), a global leader in marketing solutions, today announced a first-of-its-kind strategic partnership with Aaru, a cutting-edge AI and technology company specializing in predictive simulations for human behavior.
Former Nebraska State Senator Tony Fulton Re-Joins NioCorp Board After Serving as Nebraska's 22nd Tax Commissioner and Director of the Nebraska Department of Revenue CENTENNIAL, CO / ACCESS Newswire / August 11, 2025 / NioCorp Developments Ltd. ("NioCorp" or the "Company") (NASDAQ:NB) is pleased to announce that Tony Fulton has re-joined the Company's Board of Directors (the "Board"), filling a current vacancy.
Americas Gold and Silver Reports Positive Q2 2025 Results and Provides Development Update on Operational Improvements and Projects Underway — Neutral
USAS Business Wire — August 11, 2025TORONTO--(BUSINESS WIRE)--Americas Gold and Silver Corporation (TSX: USA) (NYSE American: USAS) (“Americas” or the “Company”), a growing North American precious metals producer, reports consolidated financial and operational results for the quarter ended June 30, 2025. This earnings release should be read in conjunction with the Company's Management's Discussion and Analysis, Financial Statements and Notes to Financial Statements for the corresponding period, which have been posted on the Ameri.
Largo Announces $6 Million Secured Loan to Support Working Capital — Neutral
LGO Business Wire — August 11, 2025TORONTO--(BUSINESS WIRE)---- $LGO #cleanenergy--Largo Announces $6 Million Secured Loan to Support Working Capital.
Ligand Announces Proposed Offering of $400 Million of Convertible Senior Notes Due 2030 — Neutral
LGND GlobeNewsWire — August 11, 2025JUPITER, Fla., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) (“Ligand”) announced today its intention to offer $400.0 million aggregate principal amount of convertible senior notes due 2030 (the “notes”) in a private placement (the “offering”) to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”), subject to market conditions and other factors.
Successful completion of strategic reorganization, reducing debt by $1.15 billion. In connection with emergence on 6/24/25, fiscal Q2 consists of a "Predecessor" period from 3/30/25 to 6/24/25, and a “Successor” period from 6/25/25 to 6/30/25
Ceva, Inc. Announces Second Quarter 2025 Financial Results — Neutral
CEVA PRNewsWire — August 11, 2025Total revenue of $25.7 million, up 6% sequentially 4 licensing deals signed for NeuPro NPUs, marking pivotal moment for Ceva's AI business 2 strategic automotive IP agreements secured with U.S. companies for V2X and 4D radar Ceva-powered device shipments of 488 million units in the quarter, including record cellular IoT and Wi-Fi 6 shipments Surpassed 20 billion Ceva-powered device milestone, underscoring technology leadership and deep industry partnerships for more than two decades Repurchased 300,000 shares of Ceva stock for approximately $6.2 million during the quarter ROCKVILLE, Md. , Aug. 11, 2025 /PRNewswire/ -- Ceva, Inc. (NASDAQ: CEVA), the leading licensor …
U.S. GoldMining Advances Planning With State of Alaska Officials for Critical Road Infrastructure to the Whistler Gold-Copper Project, Alaska — Neutral
USGO PRNewsWire — August 11, 2025ANCHORAGE, Alaska , Aug. 11, 2025 /PRNewswire/ - U.S. GoldMining Inc. (NASDAQ: USGO) ("U.S. GoldMining" or the "Company") is pleased to provide an update with respect to discussions with representatives from the State of Alaska and Matanuska-Susitna Borough ("MSB") regarding plans to advance the West Susitna Access Project ("WSAP"). The Company is very pleased to report, based on discussions to date, continued strong support at all levels of government for the Whistler Gold-Copper Project ("Whistler" or the "Project") and that all critical elements of the WSAP, which will connect Whistler with existing highway, rail, power and port infrastructure, are moving …
CECO Environmental Announces Upcoming Investor Conferences — Neutral
CECO GlobeNewsWire — August 11, 2025ADDISON, Texas, Aug. 11, 2025 (GLOBE NEWSWIRE) -- CECO Environmental Corp. (Nasdaq: CECO), a leading environmentally focused, diversified industrial company whose solutions protect people, the environment and industrial equipment, today announces that CECO management will participate at the following investor conferences:
Fresenius Medical Care announces first tranche of its share buyback program of up to EUR 600 million as part of its new capital allocation framework — Neutral
FMS PRNewsWire — August 11, 2025Total volume of the initial share buyback is up to EUR 1 billion over two years Share buyback to take place until August 10, 2027 BAD HOMBURG, Germany , Aug. 11, 2025 /PRNewswire/ -- Fresenius Medical Care (FME), the world's leading provider of products and services for individuals with renal diseases, announced the launch of the first tranche of its initial EUR 1 billion share buyback, which is part of its new capital allocation framework as presented at its Capital Markets Day on June 17. Today, the first tranche of up to EUR 600 million was initiated, which is planned …
Powerfleet Drives SaaS Flywheel in Q1 FY2026: 6% Sequential Services Growth, Margin Expansion, and Strong Progress Towards Achieving its EBITDA Expansion Targets — Neutral
AIOT PRNewsWire — August 11, 2025Quarterly services revenue jumped by 6% sequentially to $86.5 million, increasing from $81.8 million in Q4'25. Total revenue grew by 38% year-over-year to $104.1million driven by strength in services revenue, which increased to a record high of 83% of total revenue.
Stoke Therapeutics and Biogen Announce First Patient Dosed in Phase 3 EMPEROR Study of Zorevunersen, a Potential Disease-Modifying Treatment for Dravet Syndrome — Neutral
BIIB STOK Business Wire — August 11, 2025BEDFORD, Mass., & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine, and Biogen Inc. (Nasdaq: BIIB), today announced that the first patient has been dosed in the global Phase 3 EMPEROR study of zorevunersen for the treatment of Dravet syndrome. Zorevunersen, an investigational antisense oligonucleotide, has the potential to be the first disease-modifyi.
Quanterix to Present at the Canaccord Genuity 45th Annual Growth Conference — Neutral
QTRX Business Wire — August 11, 2025BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that its executive leadership team will present at the Canaccord Genuity 45th Annual Growth Conference in Boston, Massachusetts on Tuesday, August 12th, at 3:30 p.m. ET. Quanterix will also host one-on-one meetings with institutional investors during the conference. Webcast Information The live webcast presentation can be acc.
DigitalOcean Announces Proposed Convertible Senior Notes Offering — Neutral
DOCN Business Wire — August 11, 2025BROOMFIELD, Colo.--(BUSINESS WIRE)--DigitalOcean Holdings, Inc. (“DigitalOcean”) (NYSE: DOCN), today announced its intent to offer, subject to market conditions and other factors, $500 million aggregate principal amount of convertible senior notes due 2030 (the “notes”) in a private offering to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). DigitalOcean also intends to grant the initial.
ALT5 Sigma Corporation Announces $1.5 Billion Registered Direct Offering and Concurrent Private Placement to Initiate World Liberty Financial $WLFI Treasury Strategy — Neutral
ALTS Business Wire — August 11, 2025LAS VEGAS--(BUSINESS WIRE)--ALT5 Sigma Corporation (NASDAQ: ALTS)(FRA: 5AR1) (the “Company” or “ALT5”) today announced that it has entered into definitive agreements for the issuance and sale of an aggregate of up to 100,000,000 of its shares of common stock (or common stock equivalents in lieu thereof) in a registered direct offering (the “Registered Direct Offering”) at a purchase price of $7.50 per share. In a concurrent private placement (the “Private Placement Offering” and, together with.
KalVista Pharmaceuticals Announces Maintenance of Orphan Designation for Sebetralstat in European Union — Neutral
KALV Business Wire — August 11, 2025CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced that the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency (EMA) confirmed maintenance of orphan designation for sebetralstat, underscoring the critical unmet need that sebetralstat addresses in the European Union (EU). Sebetralstat, a novel, oral plasma kallikrein inhibitor, has received a positive CHMP opinion for the treatment of acute attacks of.
Builders FirstSource Announces Dual Listing on NYSE Texas — Neutral
BLDR Business Wire — August 11, 2025IRVING, Texas--(BUSINESS WIRE)--Builders FirstSource, Inc. (NYSE: BLDR) announced today the dual listing of its common stock on NYSE Texas, the newly launched fully electronic equities exchange headquartered in Dallas, TX. The Company will maintain its primary listing on the New York Stock Exchange and trade with the same “BLDR” ticker symbol on NYSE Texas. Peter Jackson, CEO of Builders FirstSource, commented: “We are pleased to be among the founding members listed on the NYSE Texas. This dual.